SODIUM-HF Trial

Miles Marchand presented the SODIUM-HF Trial which was an international, open-label, randomised, controlled trial comparing usual care according to local guidelines or a low sodium diet of less than 100 mmol (ie, <1500 mg/day) among patients with chronic heart failure (NYHA 2–3) and receiving optimally tolerated guideline-directed medical treatment. The primary outcome was the composite of cardiovascular-related admission to hospital, cardiovascular-related emergency department visit, or all-cause death within 12 months. The trial was presented at ACC in April and published in the Lancet.